There are a variety of treatment options available for cutaneous T and B-cell lymphoma and many patients are able to live relatively normal lives during and following therapy. Early diagnosis, cutting-edge treatment, and novel therapies provide a significant benefit to patients with cutaneous lymphomas at Smilow Cancer Hospital and throughout the world.
Yale Cancer Center continues to make innovative advances in the diagnosis and treatment of cutaneous lymphoma through the focused efforts of a ground-breaking clinical research team. Their multispecialty approach to the treatment of patients with cutaneous lymphomas has led to the development of FDA approved treatments that are now the standard of care worldwide.
Transimmunization, an innovation related to extracorporeal photochemotherapy (ECP) ,which was the first FDA approved selective immunotherapy for any cancer, is was investigated in clinical trials at Yale Cancer Center. As the scientific and clinical successor of extracorporeal photochemotherapy, it has potential to replace ECP as the standard of care for patients with advanced forms of cutaneous T-cell lymphoma.
The scientific basis of Transimmunization is the ability to stimulate the development of dendritic cells. Transimmunization is a more efficient means by which to bring these dendritic cells in contact with target cancer cells, before they are returned to the body to stimulate an anti-tumor immune response.
Extracorporeal photochemotherapy (photopheresis), which has been continually refined by the cutaneous lymphoma clinical research team at Yale, is currently being used to treat patients with CTCL in over 250 centers throughout the world and has been administered over 300,000 times.